<DOC>
	<DOCNO>NCT02707900</DOCNO>
	<brief_summary>The purpose research study 1 ) evaluate safety series injection AGS-004 product combination series Vorinostat dose 2 ) help scientist evaluate way reactivate latent ( non-acting ) HIV virus determine immune system make strong eliminate activate HIV virus .</brief_summary>
	<brief_title>Pilot Trial Effect Vorinostat AGS-004 Persistent HIV-1 Infection</brief_title>
	<detailed_description>Purpose : Phase I study measure potential AGS-004 combine Vorinostat : 1 ) stimulate expression persistent proviral HIV rest CD4+ cell , 2 ) generate HIV-specific immune response , 3 ) combine , clear persistent infection HIV-infected participant viral replication spread inhibit uninterrupted antiretroviral therapy ( ART ) . This phase I , single-site , pilot study intend evaluate association serial AGS-004 vaccination combination serial VOR dose expression persistent proviral HIV , HIV-specific immune response , frequency rest CD4+T cell infection . Twelve participant durable viral suppression enrol . All participant receive treatment dos AGS-004 VOR continue baseline ART regimen throughout study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>1 . Confirmation HIV1 infection HIV infection define documentation license rapid HIV test HIV enzyme chemiluminescence immunoassay ( E/CIA ) test kit time prior study entry confirm licensed Western blot second antibody test method initial rapid HIV and/or E/CIA , HIV1 antigen , plasma HIV1 RNA viral load . NOTE : The term `` license '' refers US FDAapproved kit . WHO ( World Health Organization ) CDC ( Centers Disease Control Prevention ) guideline mandate confirmation initial test result must use test different one use initial assessment . A reactive initial rapid test confirm either another type rapid assay E/CIA base different antigen preparation and/or different test principle ( eg , indirect versus competitive ) , Western blot plasma HIV1 RNA viral load . 2 . Ages ≥ 18 &lt; 65 year old . 3 . Karnofsky performance status &gt; 70 . 4 . Ability willingness participant give write informed consent . Note : Due lack foreseeable benefit study volunteer , illiterate mentally incompetent volunteer enrol . 5 . Able willing provide adequate locator information . 6 . Stable ART regimen ≥ 6 month prior Screening ( Visit 1 ) . NOTE : The ART regimen define current treatment guideline . Participants may one change ART regimen tolerance , change guideline , dose simplification . 7 . On potent antiretroviral therapy , define least 2 nucleoside/nucleotide reverse transcriptase inhibitor plus nonnucleoside reverse transcriptase inhibitor , integrase inhibitor , protease inhibitor without interruption ( define miss dos two consecutive day four cumulative day ) 24 week immediately prior entry . Other potent fully suppressive antiretroviral combination consider casebycase basis . Prior change elimination medication easier dose schedule , intolerance , toxicity , reason permit alternative suppressive regimen maintain . 8 . All participant must continue cART throughout study . 9 . Able willing adhere protocol therapy judge adherent antiretroviral therapy . 10 . Plasma HIV1 RNA &lt; 50 copies/mL two time point previous 6 month never &gt; 50 copies/mL two consecutive time point last 24 month . A single unconfirmed plasma HIV RNA &gt; limit detection &lt; 1000 c/mL allow subsequent assay limit detection ; none 6 month precede study screen visit . 11 . Plasma HIV1 RNA &lt; 50 copies/mL screening ( Visit 1 ) . 12 . CD4+ cell count ≥ 300 cells/mm3 screening ( Visit 1 ) . 13 . Availability adequate sample frozen plasma ( may thaw refrozen ) draw 90 day ( preferably within 30 day ) start effective ART therapy define therapy result HIV RNA suppression detectable limit ; Note : The VL document HIV plasma sample preferably ≥8,000 copies/ml ( abstracted medical record ) . If viral load measurement associate plasma sample , another preART VL measurement ≥8,000 copies/ml use accept sample AGS004 manufacturing . A plasma sample &lt; 8,000 copies/ml may acceptable consider case case basis . 14 . No history autoimmune disease autoimmune manifestation . 15 . No active HCV infection ( HCV antibody negative measureable HCV RNA ) within 90 day enrollment ( Visit 3 ) . 16 . No active HBV infection ( measureable HBV DNA HBVsAg+ ) within 90 day enrollment ( Visit 3 ) . 17 . Ability willingness communicate effectively study personnel ; consider reliable , willing , cooperative term compliance protocol requirement . 18 . Adequate vascular access leukapheresis . 19 . Able swallow pill without difficulty . 20 . Able willing receive Intradermal ( ID ) injection without difficulty . 21 . Women write documentation follow : 1. prior hysterectomy OR bilateral oophorectomy ( removal ovary ) 2. bilateral tubal ligation 3 . Women intact uterus ovary period ≥ one year AND document FSH level indicate postmenopausal status . 22 . All male study volunteer must agree participate conception process ( e.g . active attempt impregnate , sperm donation , vitro fertilization ) , participate sexual activity could lead pregnancy , male study volunteer female partner must use two reliable method contraception ( condom , without spermicidal agent ; diaphragm cervical cap spermicide ; IUD ; hormonalbased contraception ) simultaneously receive protocolspecified study product 6 week stop study product . Participants must use reliable barrier method contraception ( condom , cervical cap ) along another form contraception . For female partner male study volunteer receive ritonavir , estrogenbased contraceptive reliable alternative method suggest . 23 . Potential participant must adequate organ function indicate follow laboratory value : System Laboratory Value Hematological Absolute neutrophil count ( ANC ) ≥1,500 /mcL Platelets ≥125,000 / mcL Hemoglobin ≥ 12 g/dL ( male ) ≥ 11.5 g/dL ( female ) Coagulation Prothrombin Time INR ≤1.5x upper limit normal ( ULN ) Chemistry K+ level Within normal limit Mg++ level ≥ 1.2 mEq/L &lt; 1.5 x ULN Glucose Screening serum glucose ≤ Grade 1 ( fast nonfasting ) Albumin ≥ 3.3 g/dL Renal Serum creatinine calculate ≤1.3 X ULN OR creatinine clearance* ≥60 mL/min potential participant creatinine level &gt; 1.3 X institutional ULN Hepatic Serum total bilirubin Total bilirubin &lt; 1.5 X ULN range , unless history Gilbert 's disease deem related treatment atazanavir . If total bilirubin elevate , direct bilirubin must &lt; 2 X ULN range . AST ( SGOT ) ALT ( SGPT ) ≤ 2.0 X ULN Lipase &lt; 1.6 X ULN Alkaline Phosphatase ≤ 2.5 X ULN *Creatinine clearance calculate per institutional standard . 1 . Known allergy sensitivity component investigational immunotherapy component VOR analog DSMO . 2 . HIV2 antibody positive absence positive HIV1 Western Blot measure Screening Visit ( Visit 1 ) . 3 . Treatment interruption ART &gt; 1 month since start ART preART plasma sample drawn . 4 . Untreated syphilis infection ( define positive rapid plasma reagin ( RPR ) without clear documentation treatment ) . 5 . Received infusion blood product , immune globulin , hematopoetic growth factor within 90 day prior study entry . 6 . All woman unless write documentation menopause ( absence period ≥ one year and/or FSH level indicate menopause ) , hysterectomy , oophorectomy , tubal ligation . 7 . All male participant expect father child within project duration study . 8 . Use follow within 90 day prior screen : immunomodulatory , cytokine , growth stimulate factor systemic cytotoxic chemotherapy , systemic corticosteroid , immune globulin , interferon , cyclosporine , methotrexate , azathioprine , antiCD25 antibody , IFN , interleukins , interleukin2 ( IL2 ) , hydroxyurea , thalidomide , sargramostim ( granulocyte macrophagecolony stimulate factor [ GMCSF ] ) , growth factor , dinitrochlorobenzene ( DNCB ) , thymosin alpha , thymopentin , inosiplex , polyribonucleoside , diticarb sodium , coumadin , warfarin , Coumadin derivative anticoagulant . 9 . Use following medication carry risk torsade de pointes : amiodarone , arsenic trioxide , astemizole , bepridil , chloroquine , chlorpromazine , cisapride , clarithromycin , diopyramide , dofetilide , domperidone , droperidol , erythromycin , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozidine , probucol , procanimide , quinidine , sotalol , sparfloxacxin , terfenadine , thioridizine . 10 . Receipt compound HDAC inhibitorlike activity , valproic acid within 30 day prior screen . Potential participant may enroll 30day washout period . 11 . Any investigational antiretroviral agent use CCR5 inhibitor Screening . 12 . Use antiretroviral medication coadministered Vorinostat within 4 week first dose anytime thereafter study . 13 . If HIV care provider study investigator unable , assess study PI protocol team , construct fully active alternative ART regimen base previous resistance test and/or treatment history . 14 . Use systemic corticosteroid use topical steroid total area exceed 15 cm2 within 30 day prior Screening , anticipate need periodic use corticosteroid study . NOTE : For participant receive ritonavir ( booster protease inhibitor ( PI ) part ART regimen , concomitant use oral/systemic/topical/inhaled/intranasal corticosteroid prohibit . 15 . Any serious illness require systemic treatment hospitalization , participant must either complete therapy clinically stable therapy , opinion site investigator , least 90 day prior entry . 16 . Known history bone marrow disorder 17 . Treatment active AIDSdefining opportunistic infection within 90 day prior Screening . 18 . Any active malignancy may require chemotherapy radiation therapy . 19 . History lymph node irradiation dissection . 20 . Evidence hepatic decompensation cirrhotic participant : history ascites , hepatic encephalopathy , bleed esophageal varix . 21 . History clinical evidence significant unstable cardiac disease ( e.g. , angina , congestive heart failure , recent myocardial infarction , significant arrhythmia ) clinically significant electrocardiogram ( ECG ) abnormality . Any history cardiac rhythm disturbance require medical surgical therapy . 22 . Any history acute chronic pancreatitis . 23 . Any renal disorder deem clinically significant investigator . 24 . Active autoimmune disease condition include , limited : Rheumatoid arthritis ( RF positive arthritis current recent flare ) ; Inflammatory bowel disease/ulcerative colitis/Crohn 's Disease ; Systemic lupus erythematosis ( clinical evidence confirm ANA &gt; 1:80 ) ; Ankylosing spondylitis ; Hashimoto 's disease ; Scleroderma ; Multiple sclerosis ; Autoimmune hemolytic anemia ( AHA ) ; Thyroiditis Immune thrombocytopenic purpura ; , Type I diabetes mellitus ( insulin therapy Type II diabetes permit ) . 25 . History evidence severe illness , malignancy , immunodeficiency HIV , condition would make participant unsuitable study opinion investigator . 26 . History neoplastic disease extensive involvement bone marrow lymphatic system participant severely compromise hematopoietic function . 27 . Inability communicate study personnel . 28 . Compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric illness physical illness , e.g. , infectious disease . 29 . Prisoner recruitment participation permit . 30 . Known psychiatric substance abuse disorder would interfere participant 's ability fully cooperate requirement trial assess study investigator . 31 . Participation another investigational clinical research study ( exception antiretroviral treatment trial use FDA approve antiretroviral agent ) use investigational agent within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Vorinostat</keyword>
	<keyword>AGS-004</keyword>
	<keyword>HIV virus</keyword>
	<keyword>AIDS</keyword>
</DOC>